Form 4: SI-BONE CEO Sells Shares Under 10b5-1 Plan

SI-BONE, Inc. CEO Laura Francis sold 5,411 shares of common stock for a weighted-average price of $17.0591 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Laura Francis, Chief Executive Officer and Director of SI-BONE, Inc. (SIBN), reported a sale of common stock.
• The transaction involved the disposition of 5,411 shares of common stock on November 11, 2025.
• The shares were sold at a weighted-average price of $17.0591 per share, with individual transactions ranging from $17.00 to $17.24.
• This sale was executed pursuant to a Rule 10b5-1 trading plan established on December 13, 2024.
• Following the reported transaction, Laura Francis directly beneficially owns 419,704 shares of common stock, which includes 396,297 shares issuable upon settlement of restricted stock units.
• Additionally, 356,730 shares are indirectly beneficially owned by The David & Laura Joint Rev Tr.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage personal finances and diversify holdings without implying a change in company outlook.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence, though the pre-arranged nature mitigates this.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape within the medical device sector.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholder sentiment, as it is pre-scheduled and not indicative of new information.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale of a relatively small portion of the CEO's total holdings, executed under a 10b5-1 plan. This type of transaction is generally considered routine and does not typically signal a change in the company's fundamental prospects or management's long-term view. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

SIBN, SI-BONE, Laura Francis, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, medical devices